Design of a Phase I Drug Combination Study with Adaptive Allocation Based on Dose-Limiting Toxicity Attribution
Open Access
Abstract
Background: This article describes the adaptation of a Phase I drug combination method to incorporate dose-limiting toxicity (DLT) attribution in dose assignments. The study is motivated by the Embolden trial (NCT03240211), a Phase Ib, multicenter trial at the UVA Comprehensive Cancer Center evaluating pembrolizumab with pralatrexate (Arm A), decitabine (Arm C), or both (Arm B) in relapsed/refractory peripheral and cutaneous T cell lymphomas. Methods: While Arms A and C used monotherapy dose escalation, Arm B required simultaneous escalation of both agents, integrating drug-specific DLT attribution to guide dosing. Results: We adapted the partial order continual reassessment method (POCRM) to incorporate this attribution, ensuring appropriate de-escalation of the offending agent. Given the trial’s complexity, software modifications were necessary to evaluate design performance through simulations. Conclusions: This work underscores the importance of novel dose-finding strategies in early-phase trials and aims to promote their broader adoption for improved trial efficiency and transparency.Keywords
Funding Information
- National Cancer Institute (R01CA247932, P30 CA044579)
- Biostatistics Shared Resource, University of Virginia Cancer Center, University of Virginia (R01CA247932, P30 CA044579)
This publication has 33 references indexed in Scilit:
- Dose selection of novel anticancer drugs: exposing the gap between selected and required dosesThe Lancet Oncology, 2024
- Applications of the partial-order continual reassessment method in the early development of treatment combinationsClinical Trials, 2024
- Early phase clinical trials in oncology: Realising the potential of seamless designsEuropean Journal of Cancer, 2023
- An Open Label, Adaptive, Phase 1 Trial of High‐Dose Oral Nitazoxanide in Healthy Volunteers: An Antiviral Candidate for SARS‐CoV‐2Clinical Pharmacology & Therapeutics, 2021
- The Role of Early-Phase Design—LetterClinical Cancer Research, 2019
- The Impact of Early-Phase Trial Design in the Drug Development ProcessClinical Cancer Research, 2019
- Implementation of adaptive methods in early‐phase clinical trialsStatistics in Medicine, 2016
- Modelling semi‐attributable toxicity in dual‐agent phase I trials with non‐concurrent drug administrationStatistics in Medicine, 2016
- Continual Reassessment Method for Partial OrderingBiometrics, 2011
- A comparison of model choices for the continual reassessment method in phase I cancer trialsStatistics in Medicine, 2009